Skip to content
Clinical Trials – home
Research site

424 Military General Training Hospital

Greece Ring Road, N. Efkarpia, 564 29 Thessaloniki, Greece

  • 1 trial recruiting
  • Systemic lupus erythematosus · Type 2 diabetes mellitus · Asthma
  • Adults and children

About Specializations

424 Military General Training Hospital in Thessaloniki, Greece specialises in clinical trials of conditions such as Systemic lupus erythematosus, Type 2 diabetes mellitus, Asthma, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Autoimmune and Inflammatory Disorders

The 424 Military General Training Hospital conducts extensive research in autoimmune diseases, with particular emphasis on systemic lupus erythematosus and related connective tissue disorders. The Rheumatology Department investigates novel therapeutic approaches aimed at reducing disease activity and improving long-term management of these chronic conditions.

  • Evaluation of oral medications for systemic lupus erythematosus disease activity reduction
  • Long-term safety assessments of emerging therapies in lupus management
  • Treatment strategies for systemic sclerosis-associated interstitial lung disease
  • Novel biologics for psoriatic arthritis in patients with prior treatment inadequacy

These investigations focus on preserving organ function, particularly lung capacity in patients with systemic sclerosis, while exploring safer and more effective treatment options for individuals living with complex autoimmune conditions.

Severe Respiratory Conditions

Research at this site addresses critical needs in respiratory medicine, particularly for patients with inadequately controlled asthma. Studies examine both immediate symptom management and long-term preservation of lung function, recognizing the progressive nature of severe respiratory disease.

  • Prevention and slowing of lung function decline in moderate-to-severe asthma
  • Triple combination inhalers for severe asthma inadequately controlled by standard therapy
  • Reduction of asthma exacerbations through advanced therapeutic interventions
  • Evaluation of biologic therapies in specific asthma patient populations

The research emphasizes personalized approaches to severe asthma management, targeting both immediate clinical outcomes and the prevention of long-term respiratory deterioration in vulnerable patient populations.

Critical Care and Sepsis Management

Innovative research in critical care medicine at the facility explores precision medicine approaches to sepsis, one of the most challenging conditions in acute care settings. The investigations focus on identifying specific patient subgroups who may benefit from targeted immunomodulatory interventions.

  • Endotype-driven sepsis treatment strategies using interferon-gamma pathway modulation
  • Identification of high-risk sepsis patients through molecular profiling
  • Optimization of dosing regimens for novel immunomodulatory therapies
  • Improvement of survival outcomes in sepsis with specific immune signatures

This work represents a shift toward precision medicine in critical care, moving beyond one-size-fits-all approaches to sepsis management by targeting specific biological mechanisms driving disease severity in distinct patient populations.

Infectious Disease Therapeutics

The research site contributes to advancing treatment options for serious fungal infections, specifically candidemia. These studies evaluate adjunctive immunotherapeutic approaches that may enhance the effectiveness of standard antifungal treatments.

  • Adjunctive immunotherapy for candidemia clearance
  • Combination strategies with standard antifungal therapy
  • Safety and efficacy evaluation of interferon-based treatments in fungal infections
  • Mortality reduction in patients with bloodstream fungal infections

These investigations address the significant clinical challenge of invasive fungal infections, exploring whether immune system modulation can improve outcomes when added to conventional antimicrobial therapy.

Metabolic and Cardiovascular Disease Prevention

Research encompasses comprehensive approaches to metabolic disorders, examining both type 2 diabetes management and obesity-related complications. The studies investigate whether improved metabolic control can prevent serious cardiovascular and renal outcomes in high-risk populations.

  • Dose-response relationships of novel diabetes medications for glycemic control
  • Prevention of cardiovascular complications in obesity
  • Protection against kidney function deterioration in metabolic disease
  • Comparative effectiveness of different medication formulations and dosing schedules

The 424 Military General Training Hospital participates in trials that recognize the interconnected nature of metabolic, cardiovascular, and renal health, evaluating therapies that may simultaneously address multiple disease processes and prevent life-threatening complications.

Rare Gastrointestinal Inflammatory Conditions

Specialized research addresses eosinophilic esophagitis, a rare chronic inflammatory disorder affecting the esophagus. These investigations examine novel biologic therapies targeting the underlying immune mechanisms responsible for this condition.

  • Histologic response assessment in eosinophilic esophagitis
  • Symptom improvement evaluation in adolescent and adult patients
  • Immune-targeted therapies for food and aeroantigen-triggered esophageal inflammation
  • Long-term management strategies for chronic eosinophilic disorders

This work addresses an important unmet need in gastroenterology and immunology, as eosinophilic esophagitis represents a growing health concern with limited established treatment options, particularly affecting quality of life through difficulties with swallowing and esophageal function.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ring Road, N. Efkarpia564 29 ThessalonikiGreece
Recruiting now
1 trial
Conditions studied
10

More sites in ThessalonikiGreece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

11 clinical trials

Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Novo Nordisk A/S
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Recombinant Human Interferon Gamma 1B
  • Sponsor:Stichting Radboud universitair medisch centrum
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB
Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Sepsis

Not recruiting
Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Emapalumab
  • Sponsor:Hellenic Institute For The Study Of Sepsis
Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.